SQ-LIP-000020 · v1.3 (archived) · View current version →

How does lipedema affect quality of life, depression, and anxiety in affected patients?

Knowledge freshness = share of the 23 indexed evidence sources from the last 5 years (newest 2025, oldest 2016) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.

Supporting claims

• SCR-LIP-000167 supporting
  In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity.
  Mental and physical health burden and quality of life in Czech women with lipedema — Kunzová et al. (2025)
• SCR-LIP-000168 supporting
  In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001).
  Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024)
• SCR-LIP-000169 supporting
  In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
  Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024)
• SCR-LIP-000170 supporting
  In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance).
  Quality of life, its factors, and sociodemographic characteristics of Polish women with lipedema — Dudek et al. (2021)
• SCR-LIP-000171 supporting
  In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75).
  Lipoedema as a Social Problem. A Scoping Review — Czerwińska et al. (2021) · DOI:10.1007/s40519-019-00703-x
• SCR-LIP-000172 supporting
  In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001).
  The Difficulties in Emotional Regulation among a Cohort of Females with Lipedema — Al-Wardat et al. (2022)
• SCR-LIP-000173 supporting
  In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression.
  Depression and appearance-related distress in functioning with lipedema — Dudek et al. (2018)
• SCR-LIP-000174 supporting
  In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL.
  Health-related stigma, perceived social support, and their role in quality of life among women with lipedema — Falck et al. (2025)
• SCR-LIP-000175 supporting
  In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment.
  The Comparative Evaluation of Depression, Life Satisfaction, and Quality of Life Between Female Patients with Lipedema and Lymphedema — Yaman et al. (2025)
• SCR-LIP-000176 supporting
  In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511).
  The association between serum vitamin D and mood disorders in a cohort of lipedema patients — Al-Wardat et al. (2021)
• SCR-LIP-000178 supporting
  In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata.
  Examining the characteristic features of lipedema and the usefulness of BMI and WHtR in clinical evaluation — Czerwińska et al. (2025)
• SCR-LIP-000349 supporting
  In a survey of lipedema patients comparing self-reported stages, more advanced stage (3-4) was associated with higher rates of depression (48.3% vs 34.8%, p<0.001), social isolation (staying home 64.3% vs 44.4%), life dissatisfaction (35.7% vs 22.0%), and loss of mobility, while psychological burden such as inferiority complex (72.8%) and constantly thinking about lipedema (73.4%) was high across all stages.
  DOI:10.1007/s11136-022-03216-w
• SCR-LIP-000350 supporting
  This narrative review synthesizing 25 references reports that lipedema patients show greater emotional dysregulation and higher anxiety (Al-Wardat: 26 patients vs 26 controls via DERS/HAM-A), significant behavioral disturbances versus overweight/obese controls (Chachaj et al.), depressive/anxious symptoms associated with comorbid fibromialgia (Cagliyan Turk et al.), occupational limitations in 51–73% of respondents (Clarke et al.), and that liposuction significantly reduced depressive symptoms and improved quality of life and body image (Arndt et al.).
  DOI:10.12740/app/201427
• SCR-LIP-000351 supporting
  In a systematic review and meta-analysis of cross-sectional cohorts, women with lipedema showed reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1), plus impaired emotional well-being (64.19 vs 73.2) reflecting frequent anxiety/depression.
  DOI:10.1177/02683555251410009
• SCR-LIP-000352 supporting
  In a prospective study of lipedema patients undergoing power-assisted liposuction, PHQ-4 total scores fell from 4.47 (mild depression, above population norm) to 2.10 (p<0.001), with anxiety subscale dropping 2.47→0.93 and depression subscale 2.00→1.17, while quality-of-life satisfaction (FLZM health module 45.77→88.00), self-esteem (RSES 29.93→33.33), and emotional stability all improved significantly postoperatively.
  DOI:10.1016/j.bjps.2024.02.048
• SCR-LIP-000353 supporting
  In a cross-sectional survey of women with lipedema (n=112), WHOQOL-BREF averaged 3.12 (1-5 scale) and life satisfaction (SWLS) averaged 3.63 (below midpoint), with symptom severity explaining 13.9% of QoL variance; psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predicted QoL after controlling for symptom severity, raising explained variance to 44.4%.
  DOI:10.1007/s11136-015-1080-x
• SCR-LIP-000354 supporting
  In a national Swedish survey of women with lipedema, RAND-36 scores were 25-35 points below the age-matched general female population across all subscales (largest gap in physical role functioning, ~43 points lower in ages 60-79; smallest in emotional well-being, ~10 points), with worse physical and social functioning at higher lipedema stages and a self-reported depression prevalence of 13.5%.
  DOI:10.1186/s12905-022-02022-3
• SCR-LIP-000355 supporting
  In 511 lipedema patients, PHQ-9 averaged 10.84±6.39 with 54% at risk of moderate-to-severe depression, WHOQOL-BREF global score averaged 60.5±16.02 (lowest in physical 54.54 and psychological 51.91 domains), and quality-of-life impairment correlated with disease stage (r=0.55, p<0.001) and inversely with depression score (r=-0.775, p<0.0001).
  DOI:10.3390/jcm11102836 · DOI:10.21203/rs.3.rs-2705753/v1
• SCR-LIP-000356 supporting
  In a survey of lipedema patients, RAND-36 quality of life was significantly lower than the general Dutch female population (59.3 vs 74.9, p<0.001) and EQ-5D-3L was reduced (66.1 vs 85), with 42.0% reporting anxiety/depression and 74.1% reporting pain/discomfort (vs 31.1% in the general population).
  DOI:10.1007/s13555-018-0241-6
• SCR-LIP-000357 supporting
  In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5).
  DOI:10.1371/journal.pone.0319099

Contradictory claims

• None indexed yet.

Refining / context

• SCR-LIP-000177 refines
  Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment.
  Disability and emotional symptoms in women with lipedema: A comparison with overweight/obese women — Chachaj et al. (2024)

Major uncertainty

The central unresolved issue is whether the elevated depression and anxiety are specifically attributable to lipedema or are largely confounded by coexisting obesity/BMI: the moderate-grade study using overweight/obese controls found no mood difference after BMI adjustment, whereas a small BMI-adjusted case-control study found persistent anxiety differences — leaving the lipedema-specific mood signal unresolved. Nearly all evidence is cross-sectional and self-reported, precluding causal inference; control groups, instruments and prevalence estimates are highly heterogeneous (e.g., self-reported depression 13.5% to 48%, meta-analytic I²=83-93%); the stage-versus-burden relationship is contradictory across cohorts; and intervention (liposuction) benefits derive only from small uncontrolled single-arm series.

Version history

• SQ-LIP-000020 · v1.3 — 2026-05-31 — This update added a moderate-grade systematic review/meta-analysis quantifying HRQoL deficits, several additional large cross-sectional cohorts (including n=511 and a 239-patient Swiss cohort showing 64.4% anxiety and no stage-dependence), two narrative reviews, a Swedish national survey, and the first prospective (uncontrolled) liposuction data suggesting post-operative improvement in mood and QoL. · view this version
• SQ-LIP-000020 · v1.2 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000020 · v1.1 — 2026-05-31 — This update established the first answer for this question by indexing 12 observational studies/reviews showing reduced quality of life and elevated depression/anxiety in lipedema, while adding a key moderate-grade refinement that mood differences may disappear when comparing against BMI-matched overweight/obese controls. · view this version
• SQ-LIP-000020 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000005). · view this version

Key references

DOI:10.3389/fgwh.2025.1629077 · DOI:10.1089/lrb.2023.0038 · DOI:10.3390/life14030295 · DOI:10.1186/s12905-021-01174-y · DOI:10.3390/ijerph181910223 · DOI:10.1007/s40519-019-00703-x · DOI:10.3390/ijerph192013679 · DOI:10.1080/13548506.2018.1459750 · DOI:10.1080/07399332.2025.2499487 · DOI:10.1089/lrb.2024.0117 · DOI:10.1515/hmbci-2021-0027 · DOI:10.17219/acem/181146 · DOI:10.1186/s12905-025-03834-9 · DOI:10.1007/s11136-022-03216-w · DOI:10.12740/app/201427 · DOI:10.1177/02683555251410009 · DOI:10.1016/j.bjps.2024.02.048 · DOI:10.1007/s11136-015-1080-x · DOI:10.1186/s12905-022-02022-3 · DOI:10.3390/jcm11102836 · DOI:10.21203/rs.3.rs-2705753/v1 · DOI:10.1007/s13555-018-0241-6 · DOI:10.1371/journal.pone.0319099

← All questions